Allurion has not been banned. On the contrary, in February 2026 it received PMA (Premarket Approval) — the FDA's approval pathway that mandates clinical evidence for Class III devices (P250023, 23 February 2026). In this article, we explain the truth behind the news circulating on social media and Allurion's full legal status as of 2026.
Short Answer: Allurion Is Not Banned
At the end of 2025, certain regulatory changes regarding some medical devices and aesthetic procedures took effect in Türkiye. These changes were misinterpreted on social media as "Allurion has been banned."
The actual situation:
| Parameter | Status |
|---|---|
| FDA PMA Approval | ✓ February 2026 — Class III |
| CE Mark | ✓ Approved |
| TİTCK Registration | ✓ Registered |
| ÜTS Registration | ✓ Registered |
| Application | ✓ 60+ Authorized Clinics |
What Did the Late-2025 Regulations Bring?
In 2025, TİTCK introduced additional restrictions in Türkiye targeting certain aesthetic-purpose applications and advertisements. These regulations targeted not registered, medical-purpose devices, but rather certain aesthetic-purpose and unregulated practices.
The Allurion gastric balloon is:
- A TİTCK-registered medical device
- An approved program used with an obesity management indication
- A product that can be administered only by trained, certified physicians
Under these regulations, no restriction was placed on Allurion's use in Türkiye.
FDA PMA Approval: Why Does It Matter?
The February 2026 FDA PMA approval is a landmark development for swallowable gastric balloon technology.
What is PMA, and why does it set the bar higher?
- Lower-tier clearance pathways: Based on demonstrating that a device is "substantially equivalent" to an existing device. No clinical study is required.
- PMA: Requires that clinical safety and effectiveness be proven through an independent randomized controlled trial (RCT). It is the regulatory approval pathway that mandates clinical evidence for Class III devices.
The FDA PMA approval (P250023, 23 February 2026) is based on an independent review of clinical safety and effectiveness data. This development means that the swallowable gastric balloon, which requires no endoscopy, has gained acceptance at the PMA level in the United States.
What Does "Safety Profile Across 200,000+ Placements" Mean?
Allurion has data from more than 200,000 placements worldwide. The safety profile derived from this database:
- Serious adverse event rate: <0.2% (Ienca et al., 1,770 patients, Obes Surg 2020, PMID: 32279182)
- Placement-related deaths reported: none
- Complications requiring endoscopic intervention: rare
This safety data also formed one of the core components of the FDA PMA application.
Allurion in Türkiye as of 2026
Türkiye is a market where the Allurion Program is actively administered. In published multicenter data, the mean total body weight loss (TBWL) was reported as 14.9% (Ienca et al., 1,770 patients, Obes Surg 2020, PMID: 32279182). Individual results may vary.
The Allurion Program is offered in Türkiye through an authorized distribution network. With a network of 60+ authorized clinics, the program is still being actively administered.
Where Did the "Banned" Stories on Social Media Come From?
The sources of such content are generally as follows:
- Competitor positioning: Marketers of other weight-loss methods
- Misinterpreted regulations: TİTCK's aesthetic advertising restrictions were misreported as "all procedures have been banned"
- The 2017 U.S. FDA warning: At the time, a safety warning was issued for endoscopic balloons — Allurion was not within the scope of that warning, but this information is being conflated with the present day
- Outdated information: Before 2023, Allurion had a different approval status in some countries; its current approval status is far stronger
Frequently Asked Questions
Who can administer Allurion? Only physicians trained and certified by Allurion. Unauthorized administration violates the relevant medical device regulations and may pose a risk to patient safety.
Do the TİTCK restrictions affect Allurion advertising? There are restrictions on medical device advertising, and the authorized distribution network operates in compliance with these rules. The administration of the procedure is not affected.
Was Allurion also safe before February 2026? Yes. As a CE-marked and Türkiye TİTCK-registered device, it was administered for years. The February 2026 FDA PMA approval brought the safety and effectiveness standard up to the U.S. regulatory level.
Is a new restriction expected in 2026? There is no such development that has reached the public. Allurion Technologies maintains an active relationship with regulatory agencies worldwide.
Conclusion
As of 2026, Allurion is:
- FDA PMA Class III ✓ Approved
- CE-marked ✓
- TİTCK + ÜTS ✓ Registered
- Actively administered in Türkiye ✓
Fill out our form to get information about the program from an expert physician.
Further reading:
- Swallowable Gastric Balloon 2026 Comprehensive Guide →
- Gastric Balloon Risks →
- Clinical Evidence →
- How Does It Work? →
This content is for informational purposes only; it does not constitute legal or medical advice. For up-to-date information on regulatory matters, consult the relevant health authorities.
Legal Status in Türkiye
The Allurion Balloon is registered in Türkiye by TİTCK (the Turkish Medicines and Medical Devices Agency). The product may be administered only by physicians who are TİTCK-registered and certified by Allurion. Unauthorized administration may give rise to legal liability under the applicable regulations and may pose a risk to patient safety.
What Does FDA PMA Approval Mean?
The FDA classifies medical devices into three risk classes:
- Lower-risk classes: Cleared through a pathway based on the "equivalent to a previously marketed device" approach
- Class III: PMA (Premarket Approval) — the approval pathway where clinical evidence of effectiveness and safety is mandatory
Allurion received Class III PMA (P250023, 23 February 2026). This means the FDA itself reviewed and approved the clinical safety and effectiveness data — the approval pathway that mandates clinical evidence for Class III devices.
Where Does the "Ban" Rumor Come From?
Several sources have fueled this rumor:
-
2023–2024 NYSE notice: Allurion Technologies shares received an NYSE non-compliance notice. This is a financial matter related to the company's trading on the stock exchange — it has nothing to do with the product being banned.
-
Social media conflation: The logic of "Allurion's stock-exchange problem = product banned" spread on social media. These are two different matters.
-
Competitive disinformation: Some clinics have used this rumor to disparage a competing product.
Safety Record
Published data have reported more than 200,000 placements globally (Data on File, Allurion). In a series of 1,770 patients, the serious adverse event rate was reported as <0.2%, and the safety profile was found to be clinically acceptable (Ienca et al., Obes Surg 2020, PMID: 32279182).
FAQ — Allurion Safety and Legal Status
Is Allurion banned in Türkiye? No. It is TİTCK-registered and is legally administered.
When was FDA approval obtained? 23 February 2026 — full FDA Class III approval under number PMA P250023.
Do the stock-exchange-related news reports have anything to do with the product? No. The NYSE trading notice is a financial matter — it is unrelated to the safety or approval of the device.
Is there a CE certificate? Yes. Allurion also carries the CE mark and is legally administered in Europe as well.
Can it be administered at unauthorized clinics? No. Only physicians trained and certified by Allurion can administer it. Visit the Find a Specialist page for the list of authorized clinics.
Further reading:
This content is for informational purposes only; it does not constitute legal or medical advice. For up-to-date information on regulatory matters, consult the relevant health authorities.
The Importance of Regulatory Approvals
There is a difference between a medical device "not being banned" and "being approved." Allurion falls into the second category — not merely a lack of disapproval, but active FDA PMA Class III approval.
This distinction matters because:
- FDA Class III is the regulatory approval pathway where clinical evidence of effectiveness and safety is mandatory
- After approval, mandatory 6-month post-market reporting (PAS) processes continue (an August 2026 deadline for P250023)
- This follow-up mechanism means continuous safety monitoring
A Practical Check for Patients
Things you can ask clinics before having Allurion administered:
- Do you have a TİTCK registration certificate?
- Is the physician Allurion-certified?
- How many Allurion placements have been performed?
A clinic that cannot give clear answers to these three questions should not be chosen.
This content is for informational purposes only; it does not constitute legal or medical advice.
The Key Difference of the Allurion Program
Allurion is not just a device; it is an integrated approach that brings the capsule, the digital platform, and the clinical follow-up protocol together under a single program framework.
The three pillars of the program:
- Physical: A biodegradable capsule that creates a feeling of fullness in the stomach for 16 weeks
- Digital: Continuous monitoring with the Allurion App + smart scale + Virtual Care Suite
- Behavioral: Habit change through nutrition coaching and follow-up sessions
Without these three pillars working together, maintaining weight loss can become difficult. In a long-term study of 522 patients (Caballero et al., 2025, PMID: 40676353), it was reported that a significant portion of the weight loss achieved in the patient group that adhered to the program was maintained one year later.
When evaluating Allurion, consider the entire program, not just a "16-week balloon."
In conclusion: as of 2026, Allurion is a medical program that, with FDA Class III PMA approval, is legally and actively administered both in Türkiye and worldwide. Share your concerns with your physician and make evidence-based decisions. Documents, not rumors, should be the deciding factor.
For other topics you may be curious about regarding Allurion, you can visit the clinical evidence page and the find-a-specialist page.
An Authorized Clinic Near You
You can have the Allurion Program administered at more than 60 authorized clinics across Türkiye. For clinics in major cities:
Clinical Sources
Related Articles
Gastric Balloon Risks: FDA-Approved Safety Data (2026)
What are the risks of a gastric balloon? Current safety data for the FDA-approved Allurion Balloon, side effects, and precautions. A 2026 guide backed by clinical data.
Gastric Balloon Risks and Side Effects — Data from 200,000+ Patients
What are the risks of a gastric balloon? Allurion's safety profile and contraindications according to data from 200,000+ global placements and clinical studies.
Related Pages
Which method is right for you?
Let our specialist physicians evaluate you free of charge.
Free Pre-Assessment →